Published : 04 Dec 2025
Aagami has secured a contract extension from its publicly listed Japanese client to support US partnering for their patented, FDA-approved topical lidocaine patch.
Ongoing discussions include multiple post-CDA term sheet negotiations.
The US FDA approved the lidocaine patch in September 2025 for pain relief associated with post-herpetic neuralgia (PHN).
Preparations for launch are underway. Commercialization partners are being finalized, with US sales expected to start in the first half of 2026.
Four term sheet-level discussions are active. The US deal remains open, and Aagami invites interested companies to engage quickly, aiming to sign by January 2026.
Aagami is focused on achieving the best outcome for both their client and future licensees.